Charles Brenner

This study evaluates NAPRT expression and epigenetic regulation in pediatric rhabdomyosarcoma as a potential biomarker for NAMPT inhibitor therapy.

This study identifies G3P-ChREBP as a mechanism linking Citrin Deficiency to metabolic dysfunction by activating FGF21 and lipogenesis, affecting food and alcohol choices.

This study shows that oral Nicotinamide Riboside (NR) treatment protects retinal ganglion cells (RGCs) and optic nerve axons in DBA/2J mice, likely through increased retinal NAD+ levels, and also prevents iris depigmentation and delayed IOP elevation.

This study identifies NAMPT's phosphoribosyl-hydrolase activity as a mechanism to restrict HSV-1 infection by de-phosphoribosylating viral structural proteins.

This study shows that nicotinamide riboside (NR) alleviates Parkinson's disease symptoms in animal models but reduces dopamine levels when combined with proteasome inhibition.

This study shows that systemic NR treatment protects against retinal degeneration in three mouse models by preserving retinal function and structure and increasing NAD+ levels.